Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Medicine, Fulvestrant, Palbociclib, Metastatic breast cancer, Oncology, Internal medicine, Hormone receptor, Gynecology, Cancer, Breast cancer, HER2 negative, Turkish, Estrogen receptor